Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT00292552
Registration number
NCT00292552
Ethics application status
Date submitted
14/02/2006
Date registered
16/02/2006
Date last updated
23/03/2017
Titles & IDs
Public title
Evaluation of COPD (Chronic Obstructive Pulmonary Disease) to Longitudinally Identify Predictive Surrogate Endpoints
Query!
Scientific title
A Multicentre 3 Year Longitudinal Prospective Study to Identify Novel Endpoints and Compare These With Forced Expiratory Volume in 1 Second (FEV1) for Their Ability to Measure and Predict COPD Severity and Its Progression Over Time
Query!
Secondary ID [1]
0
0
SCO104960
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
ECLIPSE
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Pulmonary Disease, Chronic Obstructive
0
0
Query!
Condition category
Condition code
Respiratory
0
0
0
0
Query!
Chronic obstructive pulmonary disease
Query!
Intervention/exposure
Study type
Observational
Query!
Patient registry
Query!
Target follow-up duration
Query!
Target follow-up type
Query!
Description of intervention(s) / exposure
Other interventions - Novel endpoint determination
COPD subjects - Subjects with GOLD stage II-IV COPD
Smoker controls - Subjects with smoking history but normal lung function
Non-smoker controls - Normal healthy non-smokers
Other interventions: Novel endpoint determination
Novel endpoint determination
Query!
Intervention code [1]
0
0
Other interventions
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Identifying new patient subtypes and endpoints for COPD
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
3 years
Query!
Eligibility
Key inclusion criteria
Inclusion criteria:
- COPD Subjects
- A COPD subject will be eligible for inclusion in this study only if all of the
following criteria apply:
- Male or female subjects, aged 40-75 years inclusive
- A baseline (post-bronchodilator) FEV1 <80% of predicted normal and a baseline
(post-bronchodilator) FEV1/FVC ratio 70%
- Current or ex-smokers with a smoking history of at least 10 pack-years (number of pack
years = (number of cigarettes per day / 20) x number of years smoked e.g., 20
cigarettes per day for 10 years, or 10 cigarettes per day for 20 years).
- A signed and dated written informed consent is obtained prior to participation
- Able to comply with the requirements of the protocol and be available for study visits
over 3 years
Control Subjects - Current/Ex Smokers
- A control subject will be eligible for inclusion in this study only if all of the
following criteria apply:
- Male or female subjects, aged 40-75 years inclusive, who are free from significant
disease as determined by history, physical examination and screening investigations
- Baseline (post-bronchodilator) FEV1 >85% of predicted normal. FEV1/FVC ratio >70%
- Current or ex-smokers with a smoking history of at least 10 pack-years (number of pack
years = (number of cigarettes per day / 20) x number of years smoked e.g., 20
cigarettes per day for 10 years, or 10 cigarettes per day for 20 years).
- A signed and dated written informed consent is obtained prior to participation.
- Able to comply with the requirements of the protocol and be available for study visits
over 3 years
Control Subjects - Non-smokers
- A non-smoking control subject will be eligible for inclusion in this study only if all
of the following criteria apply:
- Male or female subjects, aged 40-75 years inclusive, who are free from significant
disease as determined by history, physical examination and screening investigations
- Baseline (post-bronchodilator) FEV1 >85% of predicted normal. FEV1/FVC ratio >70%
- Non-smokers with a smoking history of < 1 pack-year (number of pack years = (number of
cigarettes per day / 20) x number of years smoked).
- A signed and dated written informed consent is obtained prior to participation.
- Able to comply with the requirements of the protocol and be available for study visits
over 3 years
Query!
Minimum age
40
Years
Query!
Query!
Maximum age
75
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
Yes
Query!
Key exclusion criteria
COPD Subjects
- A COPD subject will not be eligible for inclusion in this study if any of the
following criteria apply:
- Known respiratory disorders, or disorders identified at screening/visit 1 (including
identification on the first CT scan), other than COPD (e.g.: lung cancer, sarcoidosis,
tuberculosis, lung fibrosis, cystic fibrosis)
- Known history of significant inflammatory disease, other than COPD (e.g. rheumatoid
arthritis and Lupus)
- Known to be severely alpha-1-antitrypsin deficient (PI SZ or ZZ)
- Having undergone lung surgery (e.g. lung reduction, lung transplant)
- Have cancer or have had cancer in the 5 years prior to study entry
- Serious, uncontrolled disease (including serious psychological disorders) likely to
interfere with the study or impact on subject safety
- Is enrolled in a long term blinded drug study (subjects in open label studies may be
considered and subjects in short blinded studies (approx less than 12 weeks may be
considered following consultation with sponsor) or a study where there is significant
radiation exposure (e.g.: CT scans)
- Have, in the opinion of the investigator, evidence of alcohol, drug or solvent abuse
- Have received a blood transfusion in the 4 weeks prior to study start
- Has experienced a moderate or severe exacerbation (requiring oral corticosteroid,
antibiotics or hospitalisation) within the last 4 weeks. All courses of oral
corticosteroids and antibiotics must be completed at least 2 weeks before study start
- Is on long term oral corticosteroids (long term is considered use for more than 3
consecutive months)
- Unable to walk
- Subject is a participating investigator, sub-investigator, study co-ordinator, or
employee of a participating investigator, or is an immediate family member of the
aforementioned.
Control Subjects
- A control subject will not be eligible for inclusion in this study if any of the
following criteria apply:
- Known respiratory disorders, or disorders identified at screening/visit 1 including
identification on the first CT scan (e.g.: COPD, asthma, lung cancer, sarcoidosis,
tuberculosis, lung fibrosis)
- Known history of significant inflammatory disease (eg rheumatoid arthritis and Lupus)
- Known to be severely alpha-1-antitrypsin deficient (PI SZ or ZZ)
- Having undergone lung surgery (e.g. lung reduction, lung transplant)
- Have cancer or have had cancer in the 5 years prior to study entry
- Serious, uncontrolled disease (including serious psychological disorders) likely to
interfere with the study
- Is enrolled in a long term blinded drug study (subjects in open label studies may be
considered and subjects in short blinded studies (approx less than 12 weeks may be
considered following consultation with sponsor) or a study where there is significant
radiation exposure (e.g.: CT scans)
- Have, in the opinion of the investigator, evidence of alcohol, drug or solvent abuse.
- Have received a blood transfusion in the 4 weeks prior to study start
- Is on long term oral corticosteroids (long term is considered use for more than 3
consecutive months)
- Subject is a participating investigator, sub-investigator, study co-ordinator, or
employee of a participating investigator, or is an immediate family member of the
aforementioned.
Query!
Study design
Purpose
Query!
Duration
Query!
Selection
Query!
Timing
Prospective
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/12/2005
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/02/2010
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
2747
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Arizona
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
California
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Colorado
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Connecticut
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Florida
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Maryland
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Massachusetts
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Minnesota
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Missouri
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Nebraska
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
New Hampshire
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Pennsylvania
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Rhode Island
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Texas
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Virginia
Query!
Country [16]
0
0
Bulgaria
Query!
State/province [16]
0
0
Pleven
Query!
Country [17]
0
0
Bulgaria
Query!
State/province [17]
0
0
Sofia
Query!
Country [18]
0
0
Canada
Query!
State/province [18]
0
0
British Columbia
Query!
Country [19]
0
0
Canada
Query!
State/province [19]
0
0
Nova Scotia
Query!
Country [20]
0
0
Canada
Query!
State/province [20]
0
0
Ontario
Query!
Country [21]
0
0
Canada
Query!
State/province [21]
0
0
Quebec
Query!
Country [22]
0
0
Czech Republic
Query!
State/province [22]
0
0
Praha 8
Query!
Country [23]
0
0
Denmark
Query!
State/province [23]
0
0
Hvidovre
Query!
Country [24]
0
0
Netherlands
Query!
State/province [24]
0
0
Horn
Query!
Country [25]
0
0
New Zealand
Query!
State/province [25]
0
0
Wellington
Query!
Country [26]
0
0
Norway
Query!
State/province [26]
0
0
Bergen
Query!
Country [27]
0
0
Slovenia
Query!
State/province [27]
0
0
Golnik
Query!
Country [28]
0
0
Spain
Query!
State/province [28]
0
0
Palma de Mallorca
Query!
Country [29]
0
0
Ukraine
Query!
State/province [29]
0
0
Donetsk
Query!
Country [30]
0
0
Ukraine
Query!
State/province [30]
0
0
Kiev
Query!
Country [31]
0
0
United Kingdom
Query!
State/province [31]
0
0
Midlothian
Query!
Country [32]
0
0
United Kingdom
Query!
State/province [32]
0
0
Cambridge
Query!
Country [33]
0
0
United Kingdom
Query!
State/province [33]
0
0
Liverpool
Query!
Country [34]
0
0
United Kingdom
Query!
State/province [34]
0
0
London
Query!
Country [35]
0
0
United Kingdom
Query!
State/province [35]
0
0
Manchester
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
GlaxoSmithKline
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This is a 3 year longitudinal study to identify novel endpoints and compare these with
standard measures such as forced expiratory volume in 1 second (FEV1) for their ability to
measure and predict COPD (Chronic Obstructive Pulmonary Disease) severity and its progression
over time. Control subjects (smokers and never smokers) will be recruited as comparators with
the COPD subjects.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT00292552
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
GSK Clinical Trials
Query!
Address
0
0
GlaxoSmithKline
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT00292552
Download to PDF